Comparison of the peripheral blood eosinophil count using near-patient testing and standard automated laboratory measurement in healthy, asthmatic and COPD subjects

Abstract: Near-patient testing (NPT) allows clinical decisions to be made in a rapid and convenient manner and is often cost effective. In COPD the peripheral blood eosinophil count has been demonstrated to have utility in providing prognostic information and predicting response to treatment during an acute exacerbation. For this potential to be achieved having a reliable NPT of blood eosinophil count would be extremely useful. Therefore, we investigated the use of the HemoCue® WBC Diff System and evaluated its sensitivity and specificity in healthy, asthmatic and COPD subjects. This method requires a simple skin prick of blood and was compared to standard venepuncture laboratory analysis. The HemoCue® WBC Diff System measured the peripheral blood eosinophil count in healthy, asthma and COPD subjects with very close correlation to the eosinophil count as measured by standard venepuncture. The correlations were unaffected by disease status. This method for the measurement of the peripheral blood eosinophil count has the potential to provide rapid near-patient results and thus influence the speed of management decisions in the treatment of airway diseases.

Keywords: asthma, chronic obstructive pulmonary disease, eosinophils, near-patient testing

Introduction

Modern medical practice is often constrained due to an environment of time and resource limitation, and mechanisms to counteract this are actively sought; rapid and accurate bedside diagnostic tools, such as near-patient tests (NPTs) are one such mechanism. NPTs provide rapid results and can guide treatment decisions; having been established in clinical care guidelines for the management of chronic kidney disease and diabetes. In respiratory medicine, current NPTs include the oxygen saturation probe, the peak flow meter, exhaled nitric oxide and the spirometer. Although able to provide an immediate result, these current respiratory NPTs are limited in their ability to identify treatment response. Changes in serial peak flow readings are able to confirm a history of occupational asthma and worsened outcomes following an acute exacerbation, but provide no information regarding inflammatory state or airways treatable trait. The sputum and peripheral blood eosinophil count (PBEC) has been shown to be a useful measure in determining corticosteroid response in airways disease. Exhaled nitric oxide is a good surrogate of eosinophilic airway inflammation but is affected by smoking. The HemoCue® WBC Diff System (HemoCue AB, Ängelholm, Sweden) is a portable NPT, offering a 5-point differential full blood count within 2 minutes from a single drop of blood. This technology

Correspondence: Mona Bafadhel
Respiratory Medicine Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

Kirsty Hambleton
Clare M Connolly
Catherine Borg
Joanne H Davies
Helen P Jeffers
Richard EK Russell
Mona Bafadhel
Respiratory Medicine Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

http://dx.doi.org/10.2147/COPD.S147216

Short Report

This article was published in the following Dove Press journal:
International Journal of COPD
26 September 2017
Number of times this article has been viewed

Abstract: Near-patient testing (NPT) allows clinical decisions to be made in a rapid and convenient manner and is often cost effective. In COPD the peripheral blood eosinophil count has been demonstrated to have utility in providing prognostic information and predicting response to treatment during an acute exacerbation. For this potential to be achieved having a reliable NPT of blood eosinophil count would be extremely useful. Therefore, we investigated the use of the HemoCue® WBC Diff System and evaluated its sensitivity and specificity in healthy, asthmatic and COPD subjects. This method requires a simple skin prick of blood and was compared to standard venepuncture laboratory analysis. The HemoCue® WBC Diff System measured the peripheral blood eosinophil count in healthy, asthma and COPD subjects with very close correlation to the eosinophil count as measured by standard venepuncture. The correlations were unaffected by disease status. This method for the measurement of the peripheral blood eosinophil count has the potential to provide rapid near-patient results and thus influence the speed of management decisions in the treatment of airway diseases.

Keywords: asthma, chronic obstructive pulmonary disease, eosinophils, near-patient testing

Introduction

Modern medical practice is often constrained due to an environment of time and resource limitation, and mechanisms to counteract this are actively sought; rapid and accurate bedside diagnostic tools, such as near-patient tests (NPTs) are one such mechanism. NPTs provide rapid results and can guide treatment decisions; having been established in clinical care guidelines for the management of chronic kidney disease and diabetes. In respiratory medicine, current NPTs include the oxygen saturation probe, the peak flow meter, exhaled nitric oxide and the spirometer. Although able to provide an immediate result, these current respiratory NPTs are limited in their ability to identify treatment response. Changes in serial peak flow readings are able to confirm a history of occupational asthma and worsened outcomes following an acute exacerbation, but provide no information regarding inflammatory state or airways treatable trait. The sputum and peripheral blood eosinophil count (PBEC) has been shown to be a useful measure in determining corticosteroid response in airways disease. Exhaled nitric oxide is a good surrogate of eosinophilic airway inflammation but is affected by smoking. The HemoCue® WBC Diff System (HemoCue AB, Ängelholm, Sweden) is a portable NPT, offering a 5-point differential full blood count within 2 minutes from a single drop of blood.
has been evaluated by one group in 76 patients with severe asthma (Heffler et al18) and they found there to be a good correlation between the HemoCue system and standard laboratory measurements of blood eosinophils. It is unknown how this NPT method is in patients with COPD and also in healthy adults. We thus evaluated the HemoCue WBC Diff System NPT against matched automated laboratory results to assess its sensitivity and specificity in measuring PBEC in healthy adults and patients with airways disease.

Methods
A comparison of peripheral blood leukocyte counts from the HemoCue WBC Diff NPT device against corresponding laboratory automated results (Abbott Architect ci8200; Abbott Laboratories, Abbott Park, IL, USA) was conducted from healthy controls and subjects with asthma and COPD. Whole venous blood (5 mL in ethylene-diamine-tetra-acetic acid [EDTA] prepared tube) was taken via venepuncture and delivered to the local pathology laboratory at the Oxford University Hospitals NHS Foundation Trust. Following venepuncture a pin-prick of blood was also taken (one drop, approximately 10 μL) and analyzed with the results being reported immediately. Allergy status was determined by a self-reported history of atopy. Correlations and intra-class correlation coefficients (ICCs) were calculated to measure relationships between the NPT and automated laboratory results for eosinophil, neutrophil and total leukocyte cell counts (cells ×10⁹/L). Sensitivity and specificity for identifying percentage PBEC were also calculated. Bland–Altman plots were generated to assess proportional bias. In a separate subgroup of subjects with COPD (n=20), up to three drops of blood were measured for assessment of variation with repeated sampling. The lower limit of detection of PBEC for the NPT and laboratory automated analyzer was 0.1 and 0.03×10⁹ cells/L. Ethical approval was obtained from the Leicestershire, Northamptonshire and Rutland Ethics Committee (08/H0406/189) and all volunteers provided written informed consent.

Results
In the comparison study, 41 subjects (20 men) were recruited, with a mean age (range) of 47 (23–79) years. This consisted of 19 healthy controls, 12 asthma and 10 COPD subjects. A self-reported history of atopy occurred in 11 (30%). The geometric means (95% confidence interval [CI]) for all subjects for total leukocytes, neutrophils and eosinophils measured using the NPT device were 6.3 (5.3–7.3), 3.5 (2.8–4.4) and 0.2 (0.1–0.2)×10⁹ cells/L respectively and for automated laboratory results were 7.1 (6.4–7.9), 4.3 (3.7–4.9) and 0.2 (0.1–0.2)×10⁹ cells/L respectively. For percentage eosinophils, the mean (SD) for the NPT device and automated results were 3.4 (3.6) and 3.1 (3.3) respectively. Paired analysis demonstrated no differences of PBEC between the NPT and automated laboratory analyzer for absolute and %PBEC (p=0.78 and p=0.29, respectively).

![Figure 1 (Continued)](https://www.dovepress.com/10363022-updated-bland-altman-plots-testing-the-performance-of-hemo.png)
Figure 1 (A–D) Correlation and agreement plots for total leukocyte, neutrophil and eosinophil cell counts (×10^9 cells/L) between NPT (HemoCue® WBC Diff System; HemoCue AB, Ängelholm, Sweden) and automated laboratory analyser (Abbott Architect ci8200; Abbott Laboratories, Abbott Park, IL, USA). ● Healthy volunteer controls; □ COPD; ▲ asthma. (E–H) Bland–Altman plots for total leukocyte, neutrophil and eosinophil cell counts (×10^9 cells/L), difference and average between NPT (HemoCue® WBC Diff System) and automated laboratory analyzer (Abbott Architect ci8200). Horizontal lines set at bias and upper and lower 95% CI of the bias. ● Healthy volunteer controls; □ COPD; ▲ asthma.

Abbreviations: CI, confidence interval; NPT, near-patient testing.
Strong correlations and agreement, presented in Figure 1, were seen for all subjects (total eosinophils $r=0.85$; total neutrophils $r=0.75$; and total leukocytes, $r=0.76$). The mean ICC (95% CI) for percentage PBEC was 0.89 (0.74–0.95) and total PBEC was 0.98 (0.95–0.99) respectively. This indicates minimal variability between the results using NPT and automated analyzer. Atopy did not affect these results. In subjects with asthma or COPD, the NPT identified a blood eosinophil level of above or below 2%, determined by the automated laboratory analyzer as the gold standard, correctly in 20 (91%) with a sensitivity and specificity of 94% and 83% respectively. At high levels of % eosinophils proportional bias was noted (Figure 1H). In the repeated-sampling sub-study of COPD subjects, the intra-class coefficient (95% CI) of total leukocytes, total neutrophils and total eosinophils was 0.95 (0.82–0.98), 0.90 (0.74–0.97) and 0.90 (0.73–0.96) respectively, with a Cronbach Alpha reliability statistic of $>0.95$ for each measure.

**Conclusion**

The NPT HemoCue WBC Diff device, using a pin-prick of blood sample, is comparable to an automated Abbott Architect ci8200 laboratory analyzer when measuring PBEC levels and total cell counts in whole blood in both healthy volunteers and individuals with airways disease. This result was not affected by a self-reported history of allergy, is minimally variable and has excellent sensitivity in correctly identifying a percentage PBEC level $\geq2\%$. There was excellent agreement and correlation of the PBEC measured in the NPT, with very close margins of agreement. Proportional bias at higher levels of % eosinophil counts were seen, however, if this NPT was to be used for quantification of a binary outcome threshold of 2% to make treatment decisions regarding corticosteroids then this proportional bias at higher levels of PBEC is not clinically significant. Repeated sampling, in patients with COPD, was also found to be excellent. We suggest that this NPT can be used to measure eosinophil counts in patients with asthma and COPD.

**Acknowledgments**

The authors would like to acknowledge all the volunteers for their assistance in this study. Mona Bafadhel is funded by a Department of Health. Research and the views expressed are those of the authors independent research funded by the National Institute of Health.

The authors would like to acknowledge all the volunteers for their assistance in this study. Mona Bafadhel is funded by a Department of Health. Research and the views expressed are those of the authors independent research funded by the National Institute of Health.

**Author contributions**

All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Disclosure**

MB and REKR have received honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and Pfizer, and report no other conflicts of interest in this work. KH, CMC, CB, JHD, and HPJ report no conflicts of interest in this work.

**References**
